Skip to main content
AAN.com
Articles
April 24, 2001
Letter to the Editor

Why are stroke patients excluded from TPA therapy?
An analysis of patient eligibility

April 24, 2001 issue
56 (8) 1015-1020

Abstract

Background: Thrombolytic therapy for acute stroke (<3 hours) will not have a major impact on death and dependency unless it is accessible to more patients.
Objective: To determine why patients with ischemic stroke did not receive IV TPA and assess the availability of this therapy to patients with ischemic stroke.
Methods: Consecutive patients with acute ischemic stroke were prospectively identified at a university teaching hospital between October 1996 and December 1999. Additional patients with ischemic stroke were identified that were admitted to one of three other hospitals in the Calgary region during the study period. The Oxford Community Stroke Programme Classification was used to record type and side of stroke.
Results: Of 2165 stroke patients presenting to the university hospital, 1168 (53.9%) were diagnosed with ischemic stroke, 31.8% with intracranial hemorrhage (intracerebral, subarachnoid, or subdural), and 13.9% with TIA. Delay in presentation to emergency department beyond 3 hours excluded 73.1% (854/1168). Major reasons for delay included uncertain time of onset (24.2%), patients waited to see if symptoms would improve (29%), delay caused by transfer from an outlying hospital (8.9%), and inaccessibility of treating hospital (5.7%). Twenty-seven percent of patients with ischemic stroke (314/1168) were admitted within 3 hours of sympton onset and of these 84 (26.7%) patients received IV TPA. The major reasons for exclusion in this group of patients (<3 hours) were mild stroke (13.1%), clinical improvement (18.2%), perceived protocol exclusions (13.6%), emergency department referral delay (8.9%), and significant comorbidity (8.3%). Of those patients who were considered too mild or were documented to have had significant improvement, 32% either remained dependent at hospital discharge or died during hospital admission. Throughout the region there was a total of 1806 ischemic stroke patients (admitted to all four Calgary hospitals). During this study period, 4.7% received IV TPA.
Conclusions: The majority of patients are unable to receive TPA for acute ischemic stroke because they do no not reach the hospital soon enough. Of those patients presenting within 3 hours, 27% received the therapy but a further 31% were excluded because their symptoms were either considered too mild or were rapidly improving. Subsequently, a third of these patients were left either dependent or dead, bringing into question the initial decision not to treat.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med . 1995; 333: 1581–1587.
2.
Jorgenson HS, Nakayama H, Kammersgaard LP, et al. Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: simulation model. Br Med J . 1999; 919: 288–289.
3.
Katzan IL, Furlan AJ, Way LE, et al. A systematic audit of intravenous tPA in Cleveland Area Hospitals. Stroke . 1999; 30: 266.Abstract.
4.
Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet . 1999; 354: 1457–1462.
5.
Alberts MJ, Perry A, Dawson DV, et al. Effects of public and professional education on reducing the delay in presentation and referral of stroke patients. Stroke . 1992; 23: 352–356.
6.
Hill MD, Barber PA, Demchuk AM, et al. Building a brain attack team for thrombolytic therapy in acute ischemic stroke. Can Med Assoc J . 2000; 162: 1589–1593.
7.
Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull WHO . 1976; 54: 541–553.
8.
Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet . 1991; 337: 1521–1526.
9.
Kasner S, Chalela JA, Luciano JM, et al. Reliability and validity of estimating NIH stroke scale from medical records. Stroke . 1999; 30: 1534–1537.
10.
Buchan AM, Barber PA, Karbalai HG, et al. Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness. Neurology . 2000; 54: 679–684.
11.
Wardlaw JM, Yamaguchi T, del Zoppo G. Thrombolytic therapy versus control in acute ischemic stroke. Stroke module of the Cochrane Database of Systematic Reviews. Available in the Cochrane Library (database on disk and CDROM). Oxford: Update Software, 1999.
12.
Warlow CP, Dennis MS, van Gijn J, et al. Stroke. A practical guide to management. London: Blackwell Science, 1996: 146–147.
13.
Widjdicks EF, Nichols DA, Thielen KR, et al. Intra-arterial thrombolysis in acute basilar artery thromboembolism: the initial Mayo Clinic experience. Mayo Clinic Proc . 1997; 71: 1005–1013.
14.
Furlan A, Higashida R, Wechsler L, et al. Intra-arterial Prourokinase for acute ischemic stroke. The PROACT II study: a randomised controlled trial. JAMA . 1999; 282: 2003–2011.
15.
Buchan AM, Feasby TE. Stroke thrombolysis: is tissue plasminogen activator a defribrillator for the brain? Can Med Assoc J . 2000; 162: 47–48.
16.
Kothari RU, Pancioli A, Liu T, et al. Cincinnati prehospital stroke scale: reproducibility and validity. Ann Emerg Med . 1999; 33: 373–378.
17.
Kidwell CS, Starkman S, Eckstein M, et al. Identifying stroke in the field: prospective validation of the Los Angeles Prehospital Stroke Screen (LAPSS). Stroke . 2000; 31: 71–76.
18.
Levine SR, Gorman M. “Telestroke”: the application of telemedicine for stroke. Stroke . 1999; 30: 464–469.
19.
Lindley RI, Amayo E, Marshall J, et al. Acute stroke treatment in UK hospitals: the Stroke Association survey of consultant opinion. J R Coll Physicians Lond . 1995; 29: 479–484.
20.
Barber PA, Demchuk AM, Zhang J, et al, for the ASPECTS study group. Validity and reliability of a quantitative computed tomography score in predicting outcome in hyperacute stroke before thrombolytic therapy. Lancet . 2000; 355: 1670–1674.
21.
Tanne D, Gorman MJ, Bates VE, et al. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience. Stroke . 2000; 31: 370–375.
22.
Allder SJ, Moody AR, Martel AL, et al. Limitations of clinical diagnosis in acute stroke. Lancet . 1999; 354: 1523.
23.
Alexandrov AV, Felberg RA, Demchuk AM, et al. Vascular imaging predicts early clinical fluctuation in patients with acutely resolving symptoms of cerebral ischemia. Stroke . 2000; 10: 27–32.
24.
Kothari R, Sauerbeck L, Jauch E, et al. Patients’ awareness of stroke signs, symptoms, and risk factors. Stroke . 1997; 28: 1871–1875.
25.
Baron JC, von Kummer R, del Zoppo GJ. Treatment of acuteischemic stroke: challenging the concept of a rigid and universal time window. Stroke . 1995; 26: 2219–2221.
26.
Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke. The Cleveland experience. JAMA . 2000; 283: 1151–1158.
27.
Albers GW, Bates VE, Clark WM, et al. Intravenous tissue plasminogen activator for treatment of acute stroke. The Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA . 2000; 283: 1145–1150.
Letters to the Editor
20 July 2001
Reply to Fink et al.
Alastair M Buchan

We completely agree mild stroke and so called "neurologic improvement" are no guarantee of good recovery. [1]. Although a neurologic score may be suggestive of a mild stroke, the behavioral consequences can often be functionally disastrous.

In the case described by Fink et al, a patient with a right hemisphere improved (because the NIH score stroke had declined). This led to an initial decision not to treat the patient. Following transfer of this patient and sophisticated neuro imaging, although the patient improved, a large perfusion deficit was discovered. The decision was reversed and treatment was given, because of the large perfusion deficit, resulting in an extremely good neurologic outcome. Therefore, the patient was treated, despite the improvement, on the basis of persistent ischemia, rather than using the NINDS rules. The NINDS study is based on NIH scores which can be unevenly low for right hemisphere strokes (because the score is so dependent on language), i.e. a low score with right brain involvement belies the severity of the stroke.

There is an excess risk of symptomatic intracranial hemorrhage unless there is strict adherence to the NINDS criteria.[5]. By sticking to these rules we have maintained low risks of intracerebral hemorrhage and have extended our single center study of effectiveness to a national study (The Canadian Activase for Stroke Effectiveness Study - CASES) which has now collected over 1,000 under three hour stroke patients who have been treated with TPA. [6]. As described in our paper [1], we have become increasingly concerned about those patients who are excluded from TPA therapy on the basis of the NINDS rules. We found that no fewer than one -third of patients who were denied treatment because the stroke was either too mild or the neurologic score was improving ended up either dead or dependent at three months. We would presume they were at a relatively low risk of treatment induced intracerebral hemorrhage but there is no randomized data which suggests these patients would benefit from the intervention. Assuming the risk is low or lower, we believe that these patients should be studied in a randomized, prospective trial.

We too, have been very impressed with the eloquence of the CT scan. The unenhanced scan provides a surrogate for diffusion MRI. [7]. Our scoring system, the Alberta Stroke Program Early CT Score (ASPECTS) has been used both in Calgary and throughout Canada to help predict those patients who are most likely to benefit. [8]). Randomizing patients on the basis of an ASPECT score goes beyond the NINDS trial. It is our current thinking by using the ASPECT score [8]) to minimize risk, we could break out of the so called "NINDS box". For those with a good ASPECT score we could treat (or at least randomize to a new trial) patients, beyond three hours, those who wake up with a deficit or those who have an unknown time of onset. We would also propose that those patients who are judged to be either too mild or who are recovering (assuming the ASPECT score is good) might also benefit from intervention with low risks of hemorrhage.

What is exciting about the report of Fink et al, is it presages the use of a CT perfusion index (perhaps a P-ASPECT score) that will allow us to pick those patients who are too mild or who are improving but have a persistent ischemic attack (PIA) with a transient neurologic deficit. [9]). We predict that perfusion CT and careful quantitation of unenhanced CT (ASPECTS) will allow us to design trials that are more inclusive, affording safe TPA therapy to more stroke patients. It is our contention that we are excluding far too many stroke victims from TPA therapy and feel that our study of patient eligibility might predict what a new more inclusive trial might look like [1].

References:

5. Buchan AM, Barber PA, Newcommon N et al. "Effectiveness of t-PA in Acute Ischemic Stroke: Outcome Relates to Appropriateness." Neurology 2000;54:679-684.

6. Hill MD, Lawence K, Buchan AM, "Canadian Activase for Stroke Effectiveness Study (CASES): A Multi-Stakeholder Collaboration." Canadian Journal of Neurological Sciences 2001;28.

7. Barber PA, Demchuk AM, Hill MD et al. "A Comparison of CT versus MR Imaging in Acute Stroke using ASPECTS: Will the "New" replace the "Old" as the Preferred Imaging Modality?" Stroke 2001;32:325 (Abstract).

8 Barber PA, Demchuk, AM, Buchan AM. For the ASPECTS Study Group "Validity and Reliability of a Quantitative Computed Tomography Score in Predicting Outcome of Hyperacute Stroke before Thrombolytic Therapy." Lancet 2000;355:1670-1674.

9. Buchan AM, Aspects of Stroke Imaging. Canadian Journal of Neurological Sciences 2001;28:99-100.

20 July 2001
Why are stroke patients excluded from TPA therapy?: An analysis of patient eligibility
J Fink
M Selim, S Kumar, G Schlaug

The report of Barber et al. of the exclusion of stroke patients from treatment with tPA raises some important issues for stroke physicians.[1] The authors' finding that a third of the patients excluded from tPA treatment on the basis of clinical assessment of "mild" stroke severity or "improvement" ultimately had a poor outcome is of particular concern. We recently experienced an illustrative case:

An 82 year-old woman presented to an affiliated hospital 20 minutes after the sudden onset of left hemiplegia and neglect. The emergency physician contacted the stroke fellow at our hospital after his examination for advice. A CT scan was performed and reported negative. The treating physician was reluctant to proceed with tPA treatment after the CT scan because the patient had improved from complete paralysis to mild weakness on the left. The patient was immediately transferred to our hospital for expert assessment. On arrival, she was conversant. Motor deficits were mild. However, she had gaze deviation, neglect and hemisensory loss; NIHSS score 12. MRI was contraindicated due to pacemaker. Perfusion CT revealed an abnormality in the right temporal region and CT angiography (CTA) revealed occlusion of the inferior division of the right MCA. Intravenous tPA was administered. The next day, repeat CTA showed recanalization of the right MCA; her NIHSS score was 1.

It has been our impression that emergency clinical assessment of stroke severity may be particularly problematic for patients with right-hemisphere syndromes without major motor deficits, such as the patient resented. While the severity of the clinical deficits in right-hemisphere stroke may not be as immediately obvious as the dysphasia caused by left-hemisphere lesions, the resulting disability is at least as great.[2] The NIHSS has a greater weighting for aphasia than neglect.[3,4] For a given NIHSS score, the volume of right hemisphere strokes on chronic CT is larger than the volume of left hemisphere strokes.[4] We have found that 59 patients presenting with an NIHSS score 5 or less who had an MRI within 24 hours of stroke onset, the mean acute diffusion-weighted MRI lesion volume for right-hemisphere strokes was 8.8 cm [3], compared with 3.2cm [3] on the left (p=0.04). We would be interested to know what proportion of the patients in the authors' series who were excluded from treatment because of mild or improving deficits presented with right-hemisphere stroke, and whether right-hemisphere cases were over-represented in the group with subsequent poor outcome.

The inappropriate use of clinical exclusion criteria for tPA identified by the authors is of great concern. We believe that equal rigor must be used to ensure the inclusion of deserving patients for tPA treatment as that used to exclude those at greater risk of treatment complications. The current definition of "improving" stroke is too ambiguous. We agree with the authors that non-invasive neuroimaging techniques such as diffusion and perfusion MRI, MR angiography, CTA or transcranial Doppler ultrasonography can be useful in making the decision to treat with tPA when there is uncertainty on clinical grounds alone.

References

1. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;56:1015-1020.

2. Ween JE, Alexander MP, D'Esposito M, Roberts M. Factors predictive of stroke outcome in a rehabilitation setting. Neurology 1996;47:388-392.

3. Brott T, Adams HP, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-870.

4. Woo D, Broderick JP, Kothari RU, et al. Does the National Institutes of Health Stroke Scale favor left hemisphere strokes? Stroke 1999;30:2355-2359.

Information & Authors

Information

Published In

Neurology®
Volume 56Number 8April 24, 2001
Pages: 1015-1020
PubMed: 11320171

Publication History

Received: November 2, 2000
Accepted: January 6, 2001
Published online: April 24, 2001
Published in print: April 24, 2001

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

P. A. Barber, MRCP (UK)
From the Department of Clinical Neurosciences, University of Calgary, Alberta, Canada.
J. Zhang, MSc
From the Department of Clinical Neurosciences, University of Calgary, Alberta, Canada.
A. M. Demchuk, MD
From the Department of Clinical Neurosciences, University of Calgary, Alberta, Canada.
M. D. Hill, MD
From the Department of Clinical Neurosciences, University of Calgary, Alberta, Canada.
A. M. Buchan, FRCP
From the Department of Clinical Neurosciences, University of Calgary, Alberta, Canada.

Notes

Address correspondence and reprint requests to Dr. A.M. Buchan, Foothills Medical Centre, Rm. 1162, 1403 29 St. NW, Calgary, Alberta, Canada T2M 2T9; e-mail: [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Elevated systemic inflammation response index is associated with poor outcomes in minor ischemic stroke, Frontiers in Neurology, 15, (2024).https://doi.org/10.3389/fneur.2024.1492224
    Crossref
  2. The impact of dysbiosis in oropharyngeal and gut microbiota on systemic inflammatory response and short-term prognosis in acute ischemic stroke with preceding infection, Frontiers in Microbiology, 15, (2024).https://doi.org/10.3389/fmicb.2024.1432958
    Crossref
  3. Endovascular Thrombectomy for Acute Ischemic Stroke : Current Concept in Management, Journal of Korean Neurosurgical Society, 67, 4, (397-410), (2024).https://doi.org/10.3340/jkns.2023.0181
    Crossref
  4. Dual antiplatelet instead of intravenous thrombolysis for minor nondisabling acute ischemic stroke: A perspective from China, Journal of Translational Internal Medicine, 12, 1, (1-4), (2024).https://doi.org/10.2478/jtim-2023-0138
    Crossref
  5. A Randomized Controlled Trial of Tenecteplase Versus Standard of Care for Minor Ischemic Stroke with Proven Occlusion (TEMPO-2): Rational and design of a multicenter, randomized open-label clinical trial, International Journal of Stroke, 19, 7, (817-822), (2024).https://doi.org/10.1177/17474930241253702
    Crossref
  6. Clinical and Radiological Differences between Patients Diagnosed with Acute Ischemic Stroke and Chameleons at the Emergency Room: Insights from a Single-Center Observational Study, Cerebrovascular Diseases, (1-8), (2024).https://doi.org/10.1159/000540409
    Crossref
  7. Race, Ethnicity, and Gender Disparities in the Management and Outcomes of Critically Ill Adults with Acute Stroke, Critical Care Clinics, 40, 4, (709-740), (2024).https://doi.org/10.1016/j.ccc.2024.05.006
    Crossref
  8. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial, The Lancet, 403, 10444, (2597-2605), (2024).https://doi.org/10.1016/S0140-6736(24)00921-8
    Crossref
  9. Human Stem Cells and Their Future Application in Neurodegenerative Diseases, Comprehensive Hematology and Stem Cell Research, (316-324), (2024).https://doi.org/10.1016/B978-0-443-15717-2.00073-1
    Crossref
  10. THRIVE, ASTRAL, and iScore scales for predicting prognosis of mechanical thrombectomy in patients with acute ischemic stroke, Irish Journal of Medical Science (1971 -), 193, 5, (2509-2514), (2024).https://doi.org/10.1007/s11845-024-03741-2
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share